6533b837fe1ef96bd12a2603

RESEARCH PRODUCT

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC

B. WehlerChristian GrohéJ. TopschT. WehlerA. EhrlichH. Atmaca-dirikChristian Schulz

subject

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryAfatinibPhase IV TrialFirst line treatmentOncologyEgfr mutationInternal medicinemedicineOsimertinibIn patientbusinessmedicine.drug
yearjournalcountryeditionlanguage
2021-04-01Journal of Thoracic Oncology
https://doi.org/10.1016/s1556-0864(21)02031-1